Ionis Pharmaceuticals Financial Statements (IONS)
|
|
|
|
Report date
|
|
|
25.02.2022 |
22.02.2023 |
21.02.2024 |
19.02.2025 |
26.02.2026 |
|
29.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
810.5 |
587.4 |
787.6 |
705.1 |
944.0 |
|
1 058 |
|
Operating Income, bln rub |
|
|
-30.2 |
-410.2 |
-353.7 |
-475.1 |
-382.0 |
|
-352.8 |
|
EBITDA, bln rub |
? |
|
-5.19 |
-227.8 |
-235.9 |
-353.7 |
-286.7 |
|
4 537 |
|
Net profit, bln rub |
? |
|
-28.6 |
-269.7 |
-366.3 |
-453.9 |
-381.0 |
|
-326.6 |
|
|
OCF, bln rub |
? |
|
30.8 |
-274.4 |
-307.5 |
-500.9 |
-268.6 |
|
-910.6 |
|
CAPEX, bln rub |
? |
|
17.9 |
20.1 |
28.0 |
45.3 |
51.4 |
|
60.6 |
|
FCF, bln rub |
? |
|
12.9 |
-294.5 |
-335.5 |
-546.2 |
-320.0 |
|
-971.3 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
829.8 |
983.4 |
1 132 |
1 169 |
1 310 |
|
1 393 |
|
Cost of production, bln rub |
|
|
10.8 |
14.1 |
9.13 |
11.2 |
16.0 |
|
17.5 |
|
R&D, bln rub |
|
|
643.0 |
833.0 |
899.6 |
901.5 |
916.0 |
|
925.4 |
|
Interest expenses, bln rub |
|
|
9.35 |
8.12 |
81.5 |
90.5 |
73.0 |
|
79.9 |
|
|
Assets, bln rub |
|
|
2 612 |
2 534 |
2 990 |
3 004 |
3 524 |
|
3 450 |
|
Net Assets, bln rub |
? |
|
771.7 |
572.9 |
386.7 |
588.4 |
489.1 |
|
491.4 |
|
Debt, bln rub |
|
|
1 251 |
1 369 |
1 454 |
1 417 |
2 614 |
|
2 041 |
|
Cash, bln rub |
|
|
2 133 |
1 997 |
2 331 |
2 298 |
2 677 |
|
1 919 |
|
Net debt, bln rub |
|
|
-882.1 |
-628.2 |
-877.7 |
-881.1 |
-62.7 |
|
121.8 |
|
|
Ordinary share price, rub |
|
|
30.4 |
37.8 |
50.6 |
35.0 |
79.1 |
|
74.5 |
|
Number of ordinary shares, mln |
|
|
141.0 |
141.8 |
143.0 |
149.5 |
160.0 |
|
164.9 |
|
|
Market cap, bln rub |
|
|
4 291 |
5 358 |
7 234 |
5 227 |
12 658 |
|
12 288 |
|
EV, bln rub |
? |
|
3 409 |
4 729 |
6 357 |
4 346 |
12 595 |
|
12 410 |
|
Book value, bln rub |
|
|
743 |
573 |
387 |
588 |
489 |
|
491 |
|
|
EPS, rub |
? |
|
-0.20 |
-1.90 |
-2.56 |
-3.04 |
-2.38 |
|
-1.98 |
|
FCF/share, rub |
|
|
0.09 |
-2.08 |
-2.35 |
-3.65 |
-2.00 |
|
-5.89 |
|
BV/share, rub |
|
|
5.27 |
4.04 |
2.70 |
3.94 |
3.06 |
|
2.98 |
|
|
EBITDA margin, % |
? |
|
-0.64% |
-38.8% |
-29.9% |
-50.2% |
-30.4% |
|
428.9% |
|
Net margin, % |
? |
|
-3.53% |
-45.9% |
-46.5% |
-64.4% |
-40.4% |
|
-30.9% |
|
FCF yield, % |
? |
|
0.30% |
-5.50% |
-4.64% |
-10.5% |
-2.53% |
|
-7.90% |
|
ROE, % |
? |
|
-3.71% |
-47.1% |
-94.7% |
-77.1% |
-77.9% |
|
-66.5% |
|
ROA, % |
? |
|
-1.09% |
-10.6% |
-12.3% |
-15.1% |
-10.8% |
|
-9.47% |
|
|
P/E |
? |
|
-150.1 |
-19.9 |
-19.8 |
-11.5 |
-33.2 |
|
-37.6 |
|
P/FCF |
|
|
332.7 |
-18.2 |
-21.6 |
-9.57 |
-39.6 |
|
-12.7 |
|
P/S |
? |
|
5.29 |
9.12 |
9.18 |
7.41 |
13.4 |
|
11.6 |
|
P/BV |
? |
|
5.78 |
9.35 |
18.7 |
8.88 |
25.9 |
|
25.0 |
|
EV/EBITDA |
? |
|
-657.1 |
-20.8 |
-27.0 |
-12.3 |
-43.9 |
|
2.74 |
|
Debt/EBITDA |
|
|
170.0 |
2.76 |
3.72 |
2.49 |
0.22 |
|
0.03 |
|
|
R&D/CAPEX, % |
|
|
3 592% |
4 144% |
3 212% |
1 991% |
1 781% |
|
1 526% |
|
|
CAPEX/Revenue, % |
|
|
2.21% |
3.42% |
3.56% |
6.42% |
5.45% |
|
5.73% |
|
| Ionis Pharmaceuticals shareholders |
